01:58 , Jun 29, 2019 |  BioCentury  |  Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
23:16 , Jun 21, 2019 |  BC Extra  |  Company News

June 21 Company Quick Takes: FDA rejects Daiichi's AML candidate; plus Sanofi, Novartis and more

Complete response letter for Daiichi's quizartinib  Daiichi Sankyo Co. Ltd. (Tokyo:4568) said FDA issued a complete response letter for quizartinib, its candidate to treat relapsed/refractory FLT3-ITD-positive acute myelogenous leukemia (AML). In May, an FDA advisory...
17:09 , Apr 23, 2019 |  BC Innovations  |  Distillery Therapeutics

The iron replacement drug Feraheme as a leukemia therapy

DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML) Patient sample and mouse studies suggest Feraheme ferumoxytol could help treat AML with low ferroportin levels. In primary AML blasts and progenitor cells, levels of ferroportin were...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
00:51 , Mar 9, 2019 |  BC Extra  |  Clinical News

AMAG sinks after Makena misses confirmatory trial

AMAG lost $2.43 (18%) to $11.29 on Friday after reporting that intramuscular Makena hydroxyprogesterone caproate -- the drug that created a political firestorm over its pricing eight years ago -- missed the co-primary endpoints in...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
19:07 , Dec 14, 2018 |  BC Week In Review  |  Company News

AMAG to acquire Perosphere for $50M

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) will acquire Perosphere Pharmaceuticals Inc. (Danbury, Conn.) for $50 million up front. AMAG will also assume a $12 million term loan and up to $6.2 million of Perosphere's other liabilities.The deal...
21:33 , Sep 26, 2018 |  BC Extra  |  Company News

Management tracks: Merck clears path for Frazier to remain CEO

The board of Merck & Co. Inc. (NYSE:MRK) rescinded a 28-year-old policy that required CEOs to retire at age 65. CEO Kenneth Frazier, who turns 65 in December 2019, has agreed to stay in his...
23:55 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Dental

INDICATION: Dental Patient sample and rat studies suggest promoting reactive oxygen species (ROS) production with Feraheme ferumoxytol and hydrogen peroxide could help treat dental caries (tooth decay). In Streptococcus mutans biofilms cultured on enamel-like hydroxyapatite,...
23:52 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV/AIDS Cell culture studies suggest inhibiting L selectin shedding could help treat latent HIV infection. In L selectin-expressing CD4 + T cells exposed to HIV-1, a tool compound matrix metalloproteinase 1 (MMP1) inhibitor that...